Diastereomers of 1-(isopropoxycarbonyloxy) ethyl 3-cephem 4-carboxylate
    12.
    发明授权
    Diastereomers of 1-(isopropoxycarbonyloxy) ethyl 3-cephem 4-carboxylate 失效
    1-(异丙氧基羰基氧基)乙基3-头孢烯-4-羧酸酯的非对映异构体

    公开(公告)号:US5550232A

    公开(公告)日:1996-08-27

    申请号:US447229

    申请日:1995-05-22

    CPC分类号: C07D501/00

    摘要: Enterally absorbable diastereomers of 1-(isopropoxycarbonyloxy)ethyl (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-(methoxymethyl)-3-cephem-4-carboxylate of the formula I ##STR1## and their physiologically acceptable salts and also diastereomerically pure salts of the compounds of the formula II ##STR2## where HX is a mono- or polybasic acid and where X is an inorganic or organic physiologically acceptable anion, and a process for the preparation of these compounds of the formula I or II, which comprises first precipitating the more sparingly soluble diastereomer of the formula IV in the mixing together of 1 equivalent of a solution of the diastereomer mixture of the formula III with 0.2-2 equivalents of a solution of the acid component HY and separating it off by filtration, then precipitating the more readily soluble diastereomer of the formula IV from the filtration solution, it being possible for the acid component HY to be identical or different in the consecutive partial steps and any desired sequence of addition of different acid components HY being possible, and optionally further purifying the obtained salts by crystallization, are described.

    摘要翻译: 1-(异丙氧羰基氧基)乙基(6R,7R)-7- [2-(2-氨基噻唑-4-基)-2-(Z) - (甲氧基亚氨基)乙酰氨基] -3-(甲氧基甲基)-3 式I的化合物 - 头孢烯-4-羧酸酯及其生理学上可接受的盐以及式II化合物的非对映体纯盐,其中HX是单或多元酸,其中X是无机或有机的 生理学上可接受的阴离子,以及制备这些式I或II化合物的方法,其包括首先将式IV的较微溶的非对映体沉淀在1当量的式(I)的非对映体混合物的溶液中, III与0.2-2当量的酸组分HY的溶液并通过过滤分离,然后从过滤溶液中沉淀出更容易溶解的式IV的非对映异构体,酸组分HY可能相同或不同 在一起 描述了部分步骤和任何期望的不同酸组分HY的加入顺序是可能的,并且任选地通过结晶进一步纯化得到的盐。

    Ferrocene derivatives
    16.
    发明授权
    Ferrocene derivatives 失效
    二茂铁衍生物

    公开(公告)号:US4141991A

    公开(公告)日:1979-02-27

    申请号:US799972

    申请日:1977-05-24

    CPC分类号: C07F17/02

    摘要: Compounds of the formula I ##STR1## in which R represents a cycloalkenyl radical having 5 to 7 carbon atoms, in which the ethylenic double bond is not in an adjacent position to the CO-group, or a cycloalkenyl radical having 5 to 7 carbon atoms, in which the ethylenic double bond is not in an adjacent position to the CO-group, and substituted one or more times by alkyl having 1 to 4 carbon atoms, phenyl, benzyl or chlorine, process for their manufacture, medicaments containing them and their use for the treatment of sideropenia symptoms and sideropenic anaemiae.

    摘要翻译: 或其中R代表具有5-7个碳原子的环烯基,其中烯属双键不在与CO基相邻的位置,或具有5至7个碳的环烯基的式I化合物 原子,其中烯属双键不在与CO基相邻的位置,并被一个或多个被一个或多个具有1-4个碳原子的烷基取代,苯基,苄基或氯,其制备方法,含有它们的药物和 它们用于治疗铁过少症状和铁血症性贫血。

    Diastereomers of 1-(isopropoxycarbonyloxy)ethyl 3-cephem-4-carboxylate
and processes for their preparation
    19.
    发明授权
    Diastereomers of 1-(isopropoxycarbonyloxy)ethyl 3-cephem-4-carboxylate and processes for their preparation 失效
    3-头孢烯-4-羧酸1-(异丙氧基羰基氧基)乙酯的非对映异构体及其制备方法

    公开(公告)号:US5614623A

    公开(公告)日:1997-03-25

    申请号:US447249

    申请日:1995-05-22

    CPC分类号: C07D501/00

    摘要: Enterally absorbable diastereomers of 1-(isopropoxycarbonyloxy)ethyl (6R, 7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)acetamido]-3-(methoxymethyl)-3-cephem-4-carboxylate of the formula I ##STR1## and their physiologically acceptable salts and also diastereomerically pure salts of the compounds of the formula II ##STR2## where HX is a mono- or polybasic acid and where X is an inorganic or organic physiologically acceptable anion, and a process for the preparation of these compounds of the formula I or II, which comprises first precipitating the more sparingly soluble diastereomer of the formula IV in the mixing together of 1 equivalent of a solution of the diastereomer mixture of the formula III with 0.2-2 equivalents of a solution of the acid component HY and separating it off by filtration, then precipitating the more readily soluble diastereomer of the formula IV from the filtration solution, it being possible for the acid component HY to be identical or different in the consecutive steps.

    摘要翻译: 1-(异丙氧羰基氧基)乙基(6R,7R)-7- [2-(2-氨基噻唑-4-基)-2-(Z) - (甲氧基亚氨基)乙酰氨基] -3-(甲氧基甲基)-3 式I的化合物 - 头孢烯-4-羧酸酯及其生理学上可接受的盐以及式II化合物的非对映体纯盐,其中HX是单或多元酸,其中X是无机或有机的 生理学上可接受的阴离子,以及制备这些式I或II化合物的方法,其包括首先将式IV的较微溶的非对映体沉淀在1当量的式(I)的非对映体混合物的溶液中, III与0.2-2当量的酸组分HY的溶液并通过过滤分离,然后从过滤溶液中沉淀出更容易溶解的式IV的非对映异构体,酸组分HY可能相同或不同 在consecu 有步骤。